Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;17(1):74-82.

Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery(*)

Feridoun Sabzi  1 , Gholam Reza Moradi, Heidar Dadkhah, Alireza Poormotaabed, Samsam Dabiri
Affiliations

Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery(*)

Feridoun Sabzi et al. J Res Med Sci. 2012 Jan.

Abstract

Background: The low dose aprotinin consistently reduces blood and transfusion requirement in adults during cardiac surgical procedures but its effectiveness in some ethnical groups were debated and controversy about its effect on mortality and morbidity precludes its routine use. This study was designated to determine whether a low dose of aprotinin causes more mortality and morbidity when used after coronary artery bypass grafting (CABG) surgery.

Methods: In a clinical trial study, 380 patients in placebo and 273 patients in aprotinin group were enrolled. A test dose before skin incision and 2 million kallikrein inactivation units (KIU) during initiation of cardiopulmonary bypass (CPB) were given to patients. Differences in quantity of blood transfusion, morbidity and mortality were analyzed. Multivariable analysis was performed to determine risk factors for mortality.

Results: Decreased blood product transfusions and increased rate of morbidity were found in the aprotinin group. Independent predictors for increased number of transfusion were aspirin continued before operation and small body mass index (BMI) but there was a significant difference in mortality and morbidity between two groups.

Conclusions: In patients undergoing CABG procedure, low dose aprotinin is effective in attenuating post bypass coagulopathy and decreasing blood product use, but it increases morbidity.

Keywords: Aprotinin; Blood Transfusion; Coronary Artery Bypass Graft; Mortality.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests Authors have no conflict of interests.

Figures

Diagram 1
Diagram 1
Profile of the study
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2(8571):1289–91. - PubMed
    1. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320(6):365–76. - PubMed
    1. Ronald A, Dunning J. Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg. 2006;5(6):767–73. - PubMed
    1. Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek G, Owen A, et al. Aprotinin does not decrease early graft patency after coronary artery bypass gra fting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg. 1994;107(3):807–10. - PubMed
    1. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007;297(5):471–9. - PubMed

LinkOut - more resources